APA

Papadakis E., Robson N., Yeomans A., Bailey S., Laversin S., Beers S., Sayan A. E., Ashton-Key M., Schwaiger S., Stuppner H., Troppmair J., Packham G. & Cutress R. (20170131). A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. : Oncotarget.

Chicago

Papadakis Emmanouil, Robson Natalia, Yeomans Alison, Bailey Sarah, Laversin Stephanie, Beers Stephen, Sayan A Emre, Ashton-Key Margaret, Schwaiger Stefan, Stuppner Hermann, Troppmair Jakob, Packham Graham and Cutress Ramsey. 20170131. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. : Oncotarget.

Harvard

Papadakis E., Robson N., Yeomans A., Bailey S., Laversin S., Beers S., Sayan A. E., Ashton-Key M., Schwaiger S., Stuppner H., Troppmair J., Packham G. and Cutress R. (20170131). A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. : Oncotarget.

MLA

Papadakis Emmanouil, Robson Natalia, Yeomans Alison, Bailey Sarah, Laversin Stephanie, Beers Stephen, Sayan A Emre, Ashton-Key Margaret, Schwaiger Stefan, Stuppner Hermann, Troppmair Jakob, Packham Graham and Cutress Ramsey. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. : Oncotarget. 20170131.